To access this element change to forms mode OFF
Grant Award View - GA77468
ASCOLT: ASpirin for Dukes C and high risk B COLorecTal cancer. An...
GA ID:
GA77468
Agency:
Cancer Australia
Approval Date:
8-May-2020
Publish Date:
11-May-2020
Category:
Cancer
Grant Term:
13-May-2020 to 12-May-2023
Value (AUD):
$465,000.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 19/20 Improved cancer control
Grant Program:
2019 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
ASCOLT: ASpirin for Dukes C and high risk B COLorecTal cancer. An International, Multi-centre, Double Blind, Randomised Trial
Purpose:
ASCOLT, an international study co-led by the national bowel cancer trials group AGITG, tests if aspirin increases the rate of cure after bowel cancer treatment. The originally planned trial size of 1,200 patients has been increased by 387 patients to ensure the study will provide reliable results. This grant will assist AGITG to recruit 70 more patients to a total of 460, which will be 29% of the entire trial. The Investigators will also test if they can predict which patients are most likely to benefit. If positive, Aspirin, a cheap familiar medication will change practice.
GO ID:
GO Title:
2019 PdCCRS for funding commencing in 2020
Internal Reference ID:
1182824
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
The University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
The University of Sydney
Town/City:
Sydney
Postcode:
2006
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
3168
Country:
AUSTRALIA